Pharmacologic treatment of peptic ulcer bleeding

Current Treatment Options in Gastroenterology

Volumn 10, Issue 2, 2007, Pages 134-142

  Leontiadis, Grigoris I ^a   Howden, Colin W ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENATOPRAZOLE; BENZODIAZEPINE DERIVATIVE; CIMETIDINE; DIGOXIN; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; ILAPRAZOLE; INSULIN; ITRACONAZOLE; KETOCONAZOLE; LANSOPRAZOLE; METFORMIN; NIZATIDINE; OCTREOTIDE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RETINOIC ACID; SOMATOSTATIN; SULFONYLUREA DERIVATIVE; THEOPHYLLINE; TRANEXAMIC ACID; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ACUTE PANCREATITIS; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; BACTERIAL INFECTION; BLOOD TRANSFUSION; BLURRED VISION; BONE MARROW SUPPRESSION; BRADYCARDIA; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMERGENCY SURGERY; ENDOSCOPIC THERAPY; EVIDENCE BASED MEDICINE; FATIGUE; GALLSTONE; GASTRIC ULCER BLEEDING; GASTROINTESTINAL DISEASE; GYNECOMASTIA; HEALTH CARE COST; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; HYPERGASTRINEMIA; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPOTENCE; INTERSTITIAL NEPHRITIS; INTESTINE INFECTION; LIVER DYSFUNCTION; MENTAL DISEASE; META ANALYSIS; MORTALITY; MYALGIA; NAUSEA; NONHUMAN; PEPTIC ULCER BLEEDING; PHARMACEUTICAL CARE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RECURRENCE RISK; REVIEW; RISK REDUCTION; SIDE EFFECT; STEATORRHEA; SURVIVAL RATE; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOEMBOLISM; TREATMENT OUTCOME; ULCER HEALING; VISUAL DISORDER; VOMITING;

EID: 34147201274     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-007-0065-4     Document Type: Review

References (33)

1. Rockall TA, Logan RF, Devlin HB, Northfield TC: Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ 1995, 311:222-226.
2. Barkun A, Sabbah S, Enns R, et al.: The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004, 99:1238-1246.
3. Rockall TA, Logan RF, Devlin HB, Northfield TC: Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996, 38:316-321.
4. Laine L, Peterson WL: Bleeding peptic ulcer. N Engl J Med 1994, 331:717-727.
5. British Society of Gastroenterology Endoscopy Committee: Non-variceal upper gastrointestinal haemorrhage: guidelines. Gut 2002, 51(Suppl IV):iv1-iv6.
6. Barkun A, Bardou M, Marshall JK; Nonvariceal Upper GI Bleeding Consensus Conference Group: Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003, 139:843-857.
7. Cook DJ, Guyatt GH, Salena BJ, Laine LA: Endoscopic therapy for acute nonvariceal upper gastrointestinal haemorrhage: a meta-analysis. Gastroenterology 1992, 102:139-148.
8. Green FJ, Kaplan MM, Curtis LE, Levine PH: Effects of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor to prolonged gastro duodenal mucosal haemorrhage. Gastroenterology 1978, 74:38-43.
9. Collins R, Langman M: Treatment with histamine H2 antagonists in acute upper gastrointestinal hemorrhage. Implications of randomized trials. N Engl J Med 1985, 313:660-666.
10. Levine JE, Leontiadis GI, Sharma VK, Howden CW: Meta-analysis: the efficacy of intravenous H2-receptor antagonists in bleeding peptic ulcer. Aliment Pharmacol Ther 2002, 16:1137-1142.
11. Leontiadis GI, Sharma VK, Howden CW: Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2006, 1:CD002094.
12. Labenz J, Peitz U, Leusing C, et al.: Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer: a prospective randomised controlled study. Gut 1997, 40:36-41.
13. Netzer P, Gaia C, Sandoz M, et al.: Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol 1999, 94:351-357.
14. Lachman L, Howden CW: Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000, 95:57-61.
15. Spiegel BM, Dulai GS, Lim BS, et al.: The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage. Clin Gastroenterol Hepatol 2006, 4:988-997.
16. Leontiadis GI, Sharma VK, Howden CW: Enhanced efficacy of proton pump inhibitor therapy for peptic ulcer bleeding in Asia: a post hoc analysis from the Cochrane Collaboration. Aliment Pharmacol Ther 2005, 21:1055-1061.
17. Labenz J, Petersen KU, Rosch W, Koelz HR: A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2003, 17:1015-1019.
18. Dial S, Delaney JA, Barkun AN, Suissa S: Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294:2989-2995.
19. Laheij RJ, Sturkenboom MC, Hassing RJ, et al.: Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292:1955-1960.
20. Leontiadis GI, Howden CW: To establish the efficacy of PPI therapy for ulcer bleeding in the US, do we need more patients or more PPI? Am J Gastroenterol 2006, 101:2000-2002.
21. Brunner G, Luna P, Hartmann M, Wurst W: Optimizing the intragastric pH as a supportive therapy in upper GI bleeding. Yale J Biol Med 1996, 69:225-231.
22. Howden CW, Metz DC, Hunt B, et al.: Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. Aliment Pharmacol Ther 2006, 23:975-984.
23. Metz DC, Amer F, Hunt B, et al.: Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages. Aliment Pharmacol Ther 2006, 23:985-995.
24. Barkun AN, Herba K, Adam V, et al.: The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding. Aliment Pharmacol Ther 2004, 20:195-202.
25. Imperiale TF, Birgisson S: Somatostatin or octreotide compared with H2 antagonists and placebo in the management of acute nonvariceal upper gastrointestinal hemorrhage. A meta-analysis. Ann Intern Med 1997, 127:1062-1071.
26. Coraggio F, Rotondano G, Marmo R, et al.: Somatostatin in the prevention of recurrent bleeding after endoscopic haemostasis of peptic ulcer haemorrhage: a preliminary report. Eur J Gastroenterol Hepatol 1998, 10:673-676.
27. Nikolopoulou VN, Thomopoulos KC, Katsakoulis EC, et al.: The effect of octreotide as an adjunct treatment in active nonvariceal upper gastrointestinal bleeding. J Clin Gastroenterol 2004, 38:243-247.
28. Henry DA, O'Connell D: Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage. BMJ 1989, 298:1142-1146.
29. Barer D, Ogilvie A, Henry D, et al.: Cimetidine and tanexamic acid in the treatment of acute upper gastrointestinal tract bleeding. N Engl J Med 1983, 308:1571-1575.
30. Hawkey GM, Cole AT, McIntyre AS, et al.: Drug treatment in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points. Gut 2001, 49:372-379.
31. Vermeulen M, Lindsay KW, Murray GD, et al.: Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med 1984, 311:432-437.
32. Wijdicks EF, Hasan D, Lindsay KW, et al.: Short-term tranexamic acid treatment in aneurysmal subarachnoid hemorrhage. Stroke 1989, 20:1674-1679.
33. Pais SA, Nathwani RA, Dhar V, et al.: Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH. Aliment Pharmacol Ther 2006, 23:1607-1613.